Voriconazole-medicalneeds, evidence, potential for the future

Japanese Journal of Medical Mycology

Volumn 46, Issue 4, 2005, Pages 223-228

  Shirasawa, Hiromichi ^a   Nagino, Kenji ^a  

^a PFIZER INC   (United States)

Author keywords

Aspergillosis; Review; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; BRAIN; CEREBROSPINAL FLUID; CRYPTOCOCCUS; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; FUSARIUM; HUMAN; JAPAN; MYCOSIS; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; SCEDOSPORIUM; TISSUE DISTRIBUTION;

ASPERGILLUS; CANDIDA; FUSARIUM; SCEDOSPORIUM;

EID: 27744528123     PISSN: 09164804     EISSN: 09164804     Source Type: Journal    
DOI: 10.3314/jjmm.46.223     Document Type: Article

References (19)

1. Lin S-J et al.: Case-fatality rate: systematic review of the literature. Clin Infect Dis 32: 358-366, 2001.
2. Denning DW: Invasive aspergillosis. Clin Infect Dis 26: 781-805, 1998.
3. Espinel-Ingroff A: In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 36: 198-202, 1998.
4. Radford SA, Johnson EM, Warnock DW: In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens Antimicrob Agents Chemother 41: 841-843, 1997.
5. Espinel-Ingroff A: In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 39: 954-958, 2001.
6. Barry AL, Brown SD: In vitro studies of two triazole antifungal agents (voriconazole [UK- 109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 40: 1948-1949, 1996.
7. Chávez M, Bernal S, Valverde A, Gutierrez MJ, Quindós G, Mazuelos EM: In vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother 44: 697-700, 1999.
8. Nguyen MH, Yu CY: In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 42: 471-472, 1998.
9. Hitchcock CA, Andrews RJ, Lewis BGH, Troke PF: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Aspergillus, abstr. F74, p. 125. In Program and Abstracts of the 35th Inter-science Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C. 1995.
10. Troke PF, Brammer KW, Hitchcock CA, Yonren S, Sarantis N: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC), abstr. F73, p. 125. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, B.C. 1995.
11. Kubota T et al.: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60: 661-666, 1996.
12. Lutsar I et al.: Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 37: 728-732, 2003.
13. Herbrecht R et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347: 408-415, 2002.
14. Kullberg BJ et al.: Voriconazole compared with a strategy of amphotericin B followed by fluconazole for teatment of candidemia in non-neutropenic patients. Abstract of presentation ECCMID 2004.
15. Ally R et al.: A randomized, double blind, double dummy multi center trial of voriconazole and fluconazole in the treatment esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33: 1447-1454, 2001.
16. Perfect JR et al.: Voriconazole treatment for lesscomnion emerging, or refractory fungal infections. Clin Infect Dis 36: 1122-1131, 2003.
17. Walsh TJ et al.: Voriconazole compared with liposomal amhotericin B for empirical antigfungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346: 225-234, 2002.
18. http://www.cdc.gov/mmwr/PDF/RR/RR4910.pdf
19. http://clinicaltrials.gov/ct/gui/search?term=voriconazole&submit= Search